<DOC>
	<DOC>NCT02608060</DOC>
	<brief_summary>This study will examine the efficacy, safety and effect on hemoglobin levels, of once weekly subcutaneous injections of epoetin beta (30,000 IU) in anemic participants with non-Hodgkin's lymphoma, chronic lymphocytic leukemia or multiple myeloma. The anticipated study duration is 4 months, and the target sample size is 30 individuals.</brief_summary>
	<brief_title>A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adult participants with a diagnosis of nonHodgkin's lymphoma, chronic lymphocytic leukemia or multiple myeloma Anemia at Screening Visit Transfusion of red blood cells within 2 months of study drug Treatmentresistant hypertension Acute or chronic bleeding (requiring therapy) within 3 months of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>